Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt (VarenSmoke)

NYU Langone Health

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Nicotine Dependence

Treatments: Drug: placebo; Drug: varencline

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00571805

Varenicline/Smoking

GA30513U

Details and patient eligibility

About

Study of varenicline 2.0 mg/day treatment for 2 weeks with smoking test done in laboratory on Day 8 and a 1 week quit attempt from Day 8-14.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 10 cigarettes/day
• Interest in quitting smoking
• Willgness to comply with overnight smoking abbstiennce period followed by lab smoking test

Exclusion criteria

• Pregnancy
• Axis I psychiatric disorder which require treatment with psychoactive medication and would make study compliance difficult.
• Clinically significant medical condition in opinion of study clinician
• Drug or alcohol dependence inlast 12 months
• Use of other smoking cessation medications ot treatment progams in last 2 months

Trial design

0 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Description:

Varenicline

Treatment:

Drug: varencline

2

Placebo Comparator group

Description:

placebo

Treatment:

Drug: placebo